Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Nxera Pharma's Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for ...

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Neurocrine Biosciences received FDA IND acceptance for a Phase 2 study of NBI-1117567, an investigational muscarinic M1-preferring agonist discovered by Nxera Pharma. Nxera will receive a $10 million milestone payment and retains development and commercialization rights for the M1 agonist in Japan.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Alzheimer's drug development advances as FDA acceptance clears Phase 2 trial path for Nxera's partner. You can position your company to engage early with trial networks or explore regional licensing deals in Japan where Nxera keeps rights.

◆ Coverage

1 source · 26 Aug 2026

◆ Related on Wire

◆ Topics

Biotechind-acceptancemuscarinic-agonistalzheimersclinical-trialmilestone-payment